PA8777601A1 - Combinación de antagonista del receptor de progesterona con un agonista y un antagonista de la hormona liberadora de hormona luteinizante para usar en enfermedades mediadas por brca - Google Patents
Combinación de antagonista del receptor de progesterona con un agonista y un antagonista de la hormona liberadora de hormona luteinizante para usar en enfermedades mediadas por brcaInfo
- Publication number
- PA8777601A1 PA8777601A1 PA20088777601A PA8777601A PA8777601A1 PA 8777601 A1 PA8777601 A1 PA 8777601A1 PA 20088777601 A PA20088777601 A PA 20088777601A PA 8777601 A PA8777601 A PA 8777601A PA 8777601 A1 PA8777601 A1 PA 8777601A1
- Authority
- PA
- Panama
- Prior art keywords
- antagonist
- agonist
- diseases
- combination
- mediumed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
COMBINACION DEL ANTAGONISTA DEL RECEPTOR DE PROGESTERONA 11ß-(4-ACETILFENIL)-17ß-HIDROXI-17ALFA-(1,1,2,2,2,-PENTAFLUOROETIL)-ESTRA-4,9-DIEN-3-ONA, O UN DERIVADO O UN ANALOGO DE ESTE ACEPTABLE PARA USO FARMACEUTICO, AL MENOS UN AGONISTA O UN ANTAGONISTA DE LA HORMONA LIBERADORA DE HORMONA LUTEINIZANTE, Y USO DE DICHA COMBINACION PARA LA PROFILAXIS Y EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR BRCAI O BRCA2. LOS AGONISTAS Y LOS ANTAGONISTAS DE LA HORMONA LIBERADORA DE HORMONA LUTEINIZANTE QUE PUEDEN COMBINARSE CON EL COMPUESTO 11ß-(4-ACETILFENIL)-17ß-HIDROXI-17ALFA -(1,1,2,2,2, PENTAFLUOROETIL) -ESTRA-4,9-DIEN-3-ONASON, POR EJEMPLO, GONADORELINA, GOSERELINA, TRIPTORELINA, BUSERELINA, NAFARELINA, DESLORELINA, HISTRELINA, ANTIDA, RAMORELIX, CETRORELIX, ANTARELIX, ORG30850, ABARELIX, GANIRELIX Y LEUPROLINA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07090084 | 2007-04-23 | ||
US91438307P | 2007-04-27 | 2007-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8777601A1 true PA8777601A1 (es) | 2008-11-19 |
Family
ID=39872872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20088777601A PA8777601A1 (es) | 2007-04-23 | 2008-04-22 | Combinación de antagonista del receptor de progesterona con un agonista y un antagonista de la hormona liberadora de hormona luteinizante para usar en enfermedades mediadas por brca |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080261933A1 (es) |
EP (1) | EP2148682A1 (es) |
JP (1) | JP2010524996A (es) |
AR (1) | AR066233A1 (es) |
CA (1) | CA2683517A1 (es) |
CL (1) | CL2008001149A1 (es) |
PA (1) | PA8777601A1 (es) |
PE (1) | PE20090075A1 (es) |
TW (1) | TW200902029A (es) |
UY (1) | UY31042A1 (es) |
WO (1) | WO2008128786A1 (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5372996A (en) * | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
TW274552B (es) * | 1992-05-26 | 1996-04-21 | Hoechst Ag | |
JP3860841B2 (ja) * | 1996-08-30 | 2006-12-20 | ペプテック リミテッド | 持続性ペプチド放出製剤 |
US8052982B2 (en) * | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
ES2389627T3 (es) * | 1998-07-20 | 2012-10-29 | Virbac (Australia) Pty Ltd | Formulación para bioimplantes |
DK1326617T3 (da) * | 2000-10-18 | 2006-12-18 | Schering Ag | Anvendelse af 11beta- (acetylphenyl) -17beta-hydroxy-17alfa- (1,1,2,2-pentafluorethyl) estra-4,9-dien-3-on til fremstilling af et medikament til behandling af brystcancer, ovariecancer, endometrisk caner, myeloma og meningeom |
UY26966A1 (es) * | 2000-10-18 | 2002-06-20 | Schering Ag | Uso de antiprogestinas para la inducción de apoptosis en una célula |
DE10051609A1 (de) * | 2000-10-18 | 2002-05-02 | Schering Ag | Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen |
CA2428249A1 (en) * | 2000-11-16 | 2002-05-23 | Pharmacia & Upjohn Company | Combination therapy for estrogen-dependent disorders |
US20030013694A1 (en) * | 2001-05-25 | 2003-01-16 | Jens Hoffmann | Use and compositions of antiprogestins for treatment of prostate diseases |
US20040043938A1 (en) * | 2001-11-06 | 2004-03-04 | Dinesh Purandare | Combination therapy for estrogen-dependent disorders |
GB0307777D0 (en) * | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
-
2008
- 2008-04-21 EP EP08735385A patent/EP2148682A1/en not_active Withdrawn
- 2008-04-21 WO PCT/EP2008/003328 patent/WO2008128786A1/en active Application Filing
- 2008-04-21 US US12/106,566 patent/US20080261933A1/en not_active Abandoned
- 2008-04-21 CA CA002683517A patent/CA2683517A1/en not_active Abandoned
- 2008-04-21 JP JP2010504549A patent/JP2010524996A/ja active Pending
- 2008-04-22 PA PA20088777601A patent/PA8777601A1/es unknown
- 2008-04-22 TW TW097114712A patent/TW200902029A/zh unknown
- 2008-04-22 CL CL2008001149A patent/CL2008001149A1/es unknown
- 2008-04-22 UY UY31042A patent/UY31042A1/es not_active Application Discontinuation
- 2008-04-22 AR ARP080101669A patent/AR066233A1/es unknown
- 2008-04-22 PE PE2008000689A patent/PE20090075A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200902029A (en) | 2009-01-16 |
UY31042A1 (es) | 2009-01-30 |
JP2010524996A (ja) | 2010-07-22 |
AR066233A1 (es) | 2009-08-05 |
CA2683517A1 (en) | 2008-10-30 |
US20080261933A1 (en) | 2008-10-23 |
EP2148682A1 (en) | 2010-02-03 |
CL2008001149A1 (es) | 2008-11-03 |
PE20090075A1 (es) | 2009-04-24 |
WO2008128786A1 (en) | 2008-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McCarthy et al. | Update on the angiotensin AT 2 receptor | |
WO2007000036A3 (en) | Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases | |
CL2008003595A1 (es) | Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central. | |
CL2011001073A1 (es) | Compuestos derivados de 1-[{pirrolidin-3-il}-carbonil]-5-(piperazin-1-ilcarbonil)-pirrolidin, agonistas de los receptores de la melanocortina; composicion farmaceutica; utiles en el tratamiento de la obesidad, diabetes, inflamacion y disfusion erectil. | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
WO2012037380A3 (en) | Formulations of guanylate cyclase c agonists and methods of use | |
MX2022002633A (es) | Mimeticos de hepcidina conjugada. | |
UY30829A1 (es) | Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato | |
SV2006002166A (es) | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits ref. am101674 | |
BRPI0517058A (pt) | agonistas e antagonistas do receptor acoplado à proteìna g e métodos de uso | |
BRPI0809931B8 (pt) | antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo | |
CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
CL2008002051A1 (es) | Compuestos derivados de isoxazol-4-metoxi, triazol-4-metoxi o pirazol-4-metoxi, con actividad agonista del receptor x de farnesoide (fxr); composicion farmaceutica que los contiene; y el uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento de dislipidemia y enfermedades relacionadas. | |
MX2009006304A (es) | Nuevos compuestos de oxadiazol. | |
CO2021006482A2 (es) | Ureas cíclicas | |
WO2006058012A3 (en) | Gonadotropin releasing hormone receptor antagonists | |
GT201200012A (es) | Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimiento para su preparacion y su uso para el tratamiento de enfermedades | |
GT199900189A (es) | Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña. | |
ECSP045217A (es) | Derivados de n-bifenilmetil aminocicloalcancarboxamida con un sustituyente en el metilo, util como antagonistas de bradicinina | |
AR103246A1 (es) | Derivados de fgf21 y sus usos | |
MX2023013582A (es) | Regimenes de dosificacion de antagonista de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruacion. | |
MX2019006600A (es) | Agonistas duales de glp-1/glp-2. | |
CO5271696A1 (es) | Procedimiento para reducir la morbilidad y el riesgo de mortalidad | |
UY27800A1 (es) | Utilizacion de inhibidores de la transduccion de senales inducida por egfr para el tratamiento de la hiperplasia de la prostata benigna (hps) /hipertrofia de la prostata. | |
CL2009000964A1 (es) | Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior. |